Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer [version 1; peer review: 2 approved]
Breast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understandin...
Main Authors: | Georges El Hachem, Andrea Gombos, Ahmad Awada |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-04-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-591/v1 |
Similar Items
-
Triple-negative breast cancer: recent treatment advances [version 1; peer review: 2 approved]
by: Alice R T Bergin, et al.
Published: (2019-08-01) -
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer [version 3; peer review: 2 approved]
by: Hugo Veyssière, et al.
Published: (2021-06-01) -
How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]
by: Paulo Luz, et al.
Published: (2020-05-01) -
BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis
by: Maria Barton, et al.
Published: (2019-10-01) -
Recent advances in nanotheranostics for triple negative breast cancer treatment
by: Vikram Thakur, et al.
Published: (2019-10-01)